RT Journal Article
T1 Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse.
A1 Zegri-Reiriz, Isabel
A1 de Alarcón, Arístides
A1 Muñoz, Patricia
A1 Martínez Sellés, Manuel
A1 González-Ramallo, Victor
A1 Miro, Jose M
A1 Falces, Carles
A1 Gonzalez Rico, Claudia
A1 Kortajarena Urkola, Xabier
A1 Lepe, José Antonio
A1 Rodriguez Alvarez, Regino
A1 Reguera Iglesias, Jose Maria
A1 Navas, Enrique
A1 Dominguez, Fernando
A1 Garcia-Pavia, Pablo
A1 Spanish Collaboration on Endocarditis—Grupo de Apoyo al Manejo de la Endocarditis infecciosa en España (GAMES), 
K1 antibiotic prophylaxis
K1 bicuspid aortic valve
K1 endocarditis
K1 mitral valve prolapse
AB There is little information concerning infective endocarditis (IE) in patients with bicuspid aortic valve (BAV) or mitral valve prolapse (MVP). Currently, IE antibiotic prophylaxis (IEAP) is not recommended for these conditions. This study sought to describe the clinical and microbiological features of IE in patients with BAV and MVP and compare them with those of IE patients with and without IEAP indication, to determine the potential benefit of IEAP in these conditions. This analysis involved 3,208 consecutive IE patients prospectively included in the GAMES (Grupo de Apoyo al Manejo de la Endocarditis infecciosa en España) registry at 31 Spanish hospitals. Patients were classified as high-risk IE with IEAP indication (high-risk group; n = 1,226), low- and moderate-risk IE without IEAP indication (low/moderate-risk group; n = 1,839), and IE with BAV (n = 54) or MVP (n = 89). BAV and MVP patients had a higher incidence of viridans group streptococci IE than did high-risk group and low/moderate-risk group patients (35.2% and 39.3% vs. 12.1% and 15.0%, respectively; all p  IE in patients with BAV and MVP have higher rates of viridans group streptococci IE and IE from suspected odontologic origin than in other IE patients, with a clinical profile similar to that of high-risk IE patients. Our findings suggest that BAV and MVP should be classified as high-risk IE conditions and the case for IEAP should be reconsidered.
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12595
UL http://hdl.handle.net/10668/12595
LA en
DS RISalud
RD Apr 11, 2025